| W |
|
Warfarin and overanticoagulation
|
| Schliamser L., Vadasz Z., Attias D. |
| |
|
Warfarin loading with a 5-mg daily dose for the first 3 days of treatment is safe and effective for the management of patients with venous thrombosis
|
| Harper P. L., Monahan K., Baker B. |
| |
|
Warfarin-induced skin necrosis in a child with protein C deficiency and Factor V Leiden mutation
|
| Curtin J. A., Lammi A. T., Webster B. H. |
| |
|
Warfarin-resistant factor VII is a potential risk factor for thromboembolism (TE) after prosthetic heart valve replacement
|
| Giddings J. C., Ionescu A., Payne N., Fraser A. G., Butchart E. G. |
| |
|
Water soluble phosphatidylserine (C6PS) induces bovine factor Xa structural change and dimerization; do factor Xa dimers have a physiological role?
|
| Weinreb G. E., Majumder R., Lentz B. R. |
| |
|
Weight changes after acute deep venous throbosis: a prospective observational study
|
| Ageno W., Dentali F., Squizzato A., Manfredi E., Mera V., Marchesi C., Steidl L., Venco A. |
| |
|
What does the future hold?
|
| Agnelli G. |
| |
|
What is all that thrombin for?
|
| Mann K. G., Brummel K., Butenas S. |
| |
|
Which is the ideal plasma marker of endothelial damage/dysfunction in atrial fibrillation? A comparison of von Willebrand factor, E-selectin and soluble thrombomodulin
|
| Freestone B., Lip G. Y. H., Blann A., Chong A. Y. |
| |
|
Whole blood clot formation profiles in patients with Bernard Soulier's and Glanzmann's disease. Ex vivo intervention with platelets and recombinant factor VIIa
|
| Ingerslev J., Sorensen B. |
| |
|
Whole blood coagulation profiles in patients with thrombosis
|
| Poulsen L. H., Christiansen K., Ebbesen L. S., Fuglsang J., Sorensen B., Ingerslev J. |
| |
|
Whole blood coagulation response patterns to ex vivo added recombinant factor VIIa in Hemophilia A, Hemophilia B, and other inherited coagulation factor disorders
|
| Sorensen B., Ingerslev J. |
| |
|
Whole blood thromboelastography and platelet function studies with DX-88, a Kunitz-type inhibitor of kallikrein
|
| Wilbourn B. R., Mackie I. J., Jenkins A. H., Williams A., Machin S. J. |
| |
|
Why did rFVIIa have no effect in post delivery bleeding? – a case-report
|
| Heuer L., Blumenberg D., Marre P., Denter M., Sandmann G., Kruse M. J. |
| |
|
Why does the mutation G 17736A, Val 107 Val (silent), in the FIX gene cause hemophilia B in five Swedish families?
|
| Knobe K., Sjörin E., Ljung R. C. R. |
| |
|
Women with common prothrombotic mutations are not at higher risk of recurrent intrauterine fetal deaths
|
| Grandone E., Brancaccio V., Colaizzo D., Ciampa A., Cocomazzi N., Vergura P., Di Minno G., Margaglione M. |
| |
